Bone Health Technologies Awarded Third Patent For Wearable Apparatus To Treat Osteoporosis and Osteopenia

Our Bureau

Bone Health Technologies (BHT), a leading innovator of technologies for improving bone health and preventing bone diseases, today announced that the United States Patent and Trademark Office (USPTO) has awarded its third patent for the OsteoBoost Vibration Belt. US patent no 11,219,542, covers the device consisting of one or more vibrating elements that are configured for applying repeated loads to a sacrum or coccyx in order to provide therapeutic or preventative effects on osteoporosis or osteopenia to a sacrum or coccyx and bones beyond the sacrum or coccyx. This innovative application of vibration to the lumbar spine and hip area is currently being studied for the treatment of osteopenia in postmenopausal women in a clinical trial at the University of Nebraska Medical Center.

“Innovations to provide safe and effective treatment of osteopenia are desperately needed by the 64 million Americans with osteopenia and osteoporosis,” said Laura Yecies, CEO of BHT. “This patent recognizes the uniqueness of our approach, using precise, proven vibration mechanics in a wearable device that focuses on the hip and lumbar spine, the location of the most serious osteoporotic fractures.

This third patent award follows a successful 2021 for the Company. Most recently, the National Institute on Aging (NIA) of the National Institutes of Health (NIH) has awarded BHT $2.7M in a Commercialization Readiness Pilot (CRP) grant as part of the Small Business Innovation Research (SBIR) Program. In addition, BHT closed a funding round, at the One Harvard New Venture Competition, Bone Health Technologies was awarded both the One Harvard New Venture Competition Grand Prize Winner and Northern California Crowd Favorite titles and won the grand prize at the 2021 Dartmouth Entrepreneur Competition.

OsteoBoost is based on NASA research which proved that mechanical stimulation of bones through vibration would improve bone health in astronauts. Studies have shown that one 30-minute treatment with OsteoBoost reduced bone loss activity in all study participants.

For more information on the CEO appointment or Bone Health Technologies and OsteoBoost please visit:


Leave a Reply

Your email address will not be published. Required fields are marked *

Next Post

Esteemed Neurosurgery Professor and Spinal Surgeon Dr. Erica Bisson Joins Proprio As Research Advisor

Proprio, the Seattle medical technology company enabling surgeons to perform complex procedures through the combination of computer vision, machine learning, and immersive technology, is pleased to announce that Dr. Erica Bisson, MD, MPH has joined as a Research Advisor.  Dr. Bisson, Professor of Neurosurgery and Adjunct Professor of Orthopedics within […]

Subscribe Now